Rapamycin-induced hypokalaemic nephropathy in a middle-aged hypertensive male
Sir, Rapamycin-induced hypokalaemic nephropathy is rarely reported in renal transplant patients. Rapamycin, an mammalian target of rapamycin (MTOR) inhibitor, acts by preventing cell-cycle progression; it prolongs delayed graft function (DGF) and decreases repair of tubular cells [1] . There are reports of thrombotic microangiopathy when rapamycin is used with calcineurin inhibitors [2] . We hereby report a man who developed hypokalaemic nephropathy secondary to rapamycin.
A 31-year-old male with end-stage renal disease (ESRD) underwent a renal transplantation on 4 May 2005, the donor being his mother. He was inducted with dacluzimab 20 mg and immunosuppressed with ciclosporin 275 mgBD, prednisolone 35 mgOD and sodium salt of mycophenylate, 360 mgBD. He weighed 68 kgs. He had a biopsy-proven acute rejection and was switched over to rapamycin 2 mgOD, tacrolimus 1 mgBD and continued on prednisolone 12.5 mgOD. His serum creatinine stabilized at 1.6 mg/dl. On 3 August 2005,. he was hospitalized for fever. Systemic examination was normal and graft kidney was non-tender. Investigations showed: urea 107 mg/dl, creatinine 4 mg/dl, sodium 115 mmol/l, potassium 1.41 mmol/l, magnesium 1.5 mmol/l, bicarbonate 15.8 mmol/l, urine spot potassium 30 mmol/l. Urinalysis revealed active sediments with albumin 1þ. Urine culture grew E.coli-10 5 , and was treated with appropriate antibiotics. He received intravenous and oral potassium chloride for hypokalaemia. Urine output was 2000-2300 ml/day and ultrasound of the transplant kidney was normal. A renal allograft biopsy showed normal glomeruli and blood vessels, while tubules showed feathery vacuolization with no evidence of granuloma or viral inclusions (Figure 1) . Vacuolization was presumed to be due to hypokalaemia secondary to rapamycin use and the drug was withheld. Two weeks later his creatinine declined to 2.1 mg/dl with serum potassium 4.1 mmol/l. His immunosuppressants were tacrolimus 3 mgBD and prednisolone 12.5 mgOD.
At the molecular level, MTOR is necessary for maintaining the integrity and regeneration of tubular epithelial cells, which account for the majority of potassium reabsorption [1] . The sustained improvement in creatinine and potassium following discontinuation of rapamycin strongly implicates this agent in the development of hypokalaemic nephropathy. Though the incidence of hypokalaemia on rapamycin is 34%, profound hypokalaemia is very rare [3] . The temporal relationship of recovery of renal function following discontinuation of rapamycin and correction of hypokalaemia suggests rapamycin as the inciting agent for acute kidney injury. This case highlights the profound hypokalaemic response to minimal maintenance dose of rapamycin in the absence of diarrhoea, vomiting or medications causing hypokalaemia.
